These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 34711362)

  • 1. Cost-Effectiveness of Magnetic Resonance Imaging-Guided Thrombolysis for Patients With Stroke With Unknown Time of Onset.
    Muntendorf LK; Konnopka A; König HH; Boutitie F; Ebinger M; Endres M; Fiebach JB; Thijs V; Lemmens R; Muir KW; Nighoghossian N; Pedraza S; Simonsen CZ; Gerloff C; Thomalla G
    Value Health; 2021 Nov; 24(11):1620-1627. PubMed ID: 34711362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of recombinant tissue-type plasminogen activator for acute ischaemic stroke with unknown time of onset: a Markov modelling analysis from the Chinese and US perspectives.
    Zhao S; Cheng Y; Tong X; Han M; Ji L; Che Y; Hu W; Liu A
    BMJ Open; 2022 Nov; 12(11):e065133. PubMed ID: 36375982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of patient selection using penumbral-based MRI for intravenous thrombolysis.
    Earnshaw SR; Jackson D; Farkouh R; Schwamm L
    Stroke; 2009 May; 40(5):1710-20. PubMed ID: 19286581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of intravenous thrombolysis with alteplase within a 3-hour window after acute ischemic stroke.
    Ehlers L; Andersen G; Clausen LB; Bech M; Kjølby M
    Stroke; 2007 Jan; 38(1):85-9. PubMed ID: 17122430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of mechanical thrombectomy plus tissue-type plasminogen activator compared with tissue-type plasminogen activator alone for acute ischemic stroke in France.
    Kaboré N; Marnat G; Rouanet F; Barreau X; Verpillot E; Menegon P; Maachi I; Berge J; Sibon I; Bénard A
    Rev Neurol (Paris); 2019 Apr; 175(4):252-260. PubMed ID: 30642680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of thrombolysis within 4.5 hours of acute ischemic stroke: experience from Australian stroke center.
    Tan Tanny SP; Busija L; Liew D; Teo S; Davis SM; Yan B
    Stroke; 2013 Aug; 44(8):2269-74. PubMed ID: 23780955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of tissue-type plasminogen activator in the 3- to 4.5-hour time window for acute ischemic stroke.
    Tung CE; Win SS; Lansberg MG
    Stroke; 2011 Aug; 42(8):2257-62. PubMed ID: 21719767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of Endovascular Stroke Therapy: A Patient Subgroup Analysis From a US Healthcare Perspective.
    Kunz WG; Hunink MG; Sommer WH; Beyer SE; Meinel FG; Dorn F; Wirth S; Reiser MF; Ertl-Wagner B; Thierfelder KM
    Stroke; 2016 Nov; 47(11):2797-2804. PubMed ID: 27758942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter, randomized, double-blind, placebo-controlled trial to test efficacy and safety of magnetic resonance imaging-based thrombolysis in wake-up stroke (WAKE-UP).
    Thomalla G; Fiebach JB; Østergaard L; Pedraza S; Thijs V; Nighoghossian N; Roy P; Muir KW; Ebinger M; Cheng B; Galinovic I; Cho TH; Puig J; Boutitie F; Simonsen CZ; Endres M; Fiehler J; Gerloff C;
    Int J Stroke; 2014 Aug; 9(6):829-36. PubMed ID: 23490032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of thrombolysis within 4.5 hours of acute ischemic stroke in China.
    Pan Y; Chen Q; Zhao X; Liao X; Wang C; Du W; Liu G; Liu L; Wang C; Wang Y; Wang Y;
    PLoS One; 2014; 9(10):e110525. PubMed ID: 25329637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset.
    Thomalla G; Simonsen CZ; Boutitie F; Andersen G; Berthezene Y; Cheng B; Cheripelli B; Cho TH; Fazekas F; Fiehler J; Ford I; Galinovic I; Gellissen S; Golsari A; Gregori J; Günther M; Guibernau J; Häusler KG; Hennerici M; Kemmling A; Marstrand J; Modrau B; Neeb L; Perez de la Ossa N; Puig J; Ringleb P; Roy P; Scheel E; Schonewille W; Serena J; Sunaert S; Villringer K; Wouters A; Thijs V; Ebinger M; Endres M; Fiebach JB; Lemmens R; Muir KW; Nighoghossian N; Pedraza S; Gerloff C;
    N Engl J Med; 2018 Aug; 379(7):611-622. PubMed ID: 29766770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of endovascular treatment with or without intravenous thrombolysis in acute ischemic stroke.
    Qureshi AI; Akinci Y; Huang W; Ishfaq MF; Hassan AE; Siddiq F; Gomez CR
    J Neurosurg; 2023 Jan; 138(1):223-232. PubMed ID: 35901768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of recombinant tissue-type plasminogen activator within 3 hours of acute ischemic stroke: current evidence.
    Boudreau DM; Guzauskas GF; Chen E; Lalla D; Tayama D; Fagan SC; Veenstra DL
    Stroke; 2014 Oct; 45(10):3032-9. PubMed ID: 25190439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cost-utility analysis of mechanical thrombectomy as an adjunct to intravenous tissue-type plasminogen activator for acute large-vessel ischemic stroke.
    Kim AS; Nguyen-Huynh M; Johnston SC
    Stroke; 2011 Jul; 42(7):2013-8. PubMed ID: 21636817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Pharmacomechanical Catheter-Directed Thrombolysis Versus Standard Anticoagulation in Patients With Proximal Deep Vein Thrombosis: Results From the ATTRACT Trial.
    Magnuson EA; Chinnakondepalli K; Vilain K; Kearon C; Julian JA; Kahn SR; Goldhaber SZ; Jaff MR; Kindzelski AL; Herman K; Brady PS; Sharma K; Black CM; Vedantham S; Cohen DJ
    Circ Cardiovasc Qual Outcomes; 2019 Oct; 12(10):e005659. PubMed ID: 31592728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Would a Large tPA Trial for Those 4.5 to 6.0 Hours from Stroke Onset Be Good Value for Information?
    Soeteman DI; Menzies NA; Pandya A
    Value Health; 2017; 20(7):894-901. PubMed ID: 28712618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic impact of using additional diagnostic tests to better select patients with stroke for intravenous thrombolysis in the United Kingdom.
    Earnshaw SR; McDade C; Chapman AM; Jackson D; Schwamm L
    Clin Ther; 2012 Jul; 34(7):1544-58. PubMed ID: 22695225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of stent-retriever thrombectomy in combination with IV t-PA compared with IV t-PA alone for acute ischemic stroke in the UK.
    Lobotesis K; Veltkamp R; Carpenter IH; Claxton LM; Saver JL; Hodgson R
    J Med Econ; 2016 Aug; 19(8):785-94. PubMed ID: 27046347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic Thrombolysis, Catheter-Directed Thrombolysis, and Anticoagulation for Intermediate-risk Pulmonary Embolism: A Simulation Modeling Analysis.
    Kabrhel C; Ali A; Choi JG; Hur C
    Acad Emerg Med; 2017 Oct; 24(10):1235-1243. PubMed ID: 28650086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of tissue plasminogen activator in acute ischemic stroke in Iran.
    Amiri A; Goudarzi R; Amiresmaili M; Iranmanesh F
    J Med Econ; 2018 Mar; 21(3):282-287. PubMed ID: 29105528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.